Safety profile of the yellow fever vaccine Stamaril®: A 17-year review

Expert Review of Vaccines

Volumn 12, Issue 11, 2013, Pages 1351-1368

  Cottin, Pascale ^a   Niedrig, Matthias ^b   Domingo, Cristina ^b  

^a SANOFI PASTEUR   (France)

^b ROBERT KOCH INSTITUTE   (Germany)

Author keywords

adverse events; anaphylaxis; live vaccine; neurotropic disease; pharmacovigilance; pregnancy; serious adverse events; viscerotropic disease; yellow fever vaccine

Indexed keywords

AZATHIOPRINE; BENCE JONES PROTEIN; CARBIDOPA; CYCLOSPORIN; DIPHTHERIA TETANUS VACCINE; ENALAPRIL; FLUINDOSTATIN; HEPATITIS A VACCINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVODOPA; METHOTREXATE; POLIOMYELITIS VACCINE; STEROID; TRIHEXYPHENIDYL; YELLOW FEVER VACCINE;

AGE DISTRIBUTION; ALCOHOL ABUSE; ANTIGEN SPECIFICITY; ARTHRALGIA; ASTHENIA; ASTHMA; AUSTRALIA AND NEW ZEALAND; AUTISM; BORRELIA INFECTION; BRAZIL; BREAST FEEDING; CD4 LYMPHOCYTE COUNT; CEREBROVASCULAR ACCIDENT; CHOLERA; CHORIOAMNIONITIS; CLINICAL FEATURE; DIARRHEA; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ENCEPHALITIS; FATIGUE; FEVER; FIRST TRIMESTER PREGNANCY; FOLLOW UP; GAMMOPATHY; GENERAL PRACTITIONER; GROWTH RETARDATION; GUILLAIN BARRE SYNDROME; HEADACHE; HEALTH CARE PERSONNEL; HEART ATRIUM FIBRILLATION; HEART MURMUR; HEMANGIOMA; HEPATITIS A; HEPATITIS B; HIGH RISK POPULATION; HIP DYSPLASIA; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOSPADIAS; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA; INTRAUTERINE GROWTH RETARDATION; ISCHEMIC CARDIOMYOPATHY; KIDNEY COLIC; KIDNEY FAILURE; MEDICAL DICTIONARY FOR REGULATORY ACTIVITIES; MEDICAL HISTORY; MENINGITIS; MENINGOENCEPHALITIS; MENTAL HEALTH; MEXICO; MICROCEPHALY; MYALGIA; NAUSEA; NEPHRECTOMY; OLIGOHYDRAMNIOS; PALLISTER KILLIAN SYNDROME; PARESTHESIA; PARKINSON DISEASE; PREGNANCY OUTCOME; PREGNANT WOMAN; PRIORITY JOURNAL; PSYCHOMOTOR RETARDATION; RASH; REVIEW; SECOND TRIMESTER PREGNANCY; SKIN HEMANGIOMA; SOUTH AMERICA; SPONTANEOUS ABORTION; TACHYPNEA; TETANUS PROPHYLAXIS; THIRD TRIMESTER PREGNANCY; THYMECTOMY; TYPHOID FEVER; UNITED KINGDOM; URINARY TRACT INFECTION; URINARY TRACT MALFORMATION; URTICARIA; VOLUNTARY REPORTING; VOMITING; YELLOW FEVER;

DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; RISK ASSESSMENT; YELLOW FEVER VACCINE;

EID: 84887359897     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2013.836320     Document Type: Review

References (68)

1. Staples Je GM, Fischer M; Centers for Disease Control and Prevention (CDC). Yellow fever vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. Recomm. Rep. 30(59), 1-27 (2010
2. Jentes ES, Poumerol G, Gershman MD et al. The revised global yellow fever risk map and recommendations for vaccination, 2010: Consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever. Lancet Infect. Dis. 11(8), 622-632 (2011
3. Monath TP, Cetron MS, Teuwen DE. Yellow fever. In: Vaccines. Plotkin SA, Mortimer EA, Offit PA, (Eds). Philadelphia, Saunders (2008
4. Fever, jaundice, and multiple organ system failure associated with 17D-derived yellow fever vaccination, 1996-2001. MMWR. Morb. Mortal. Wkly Rep. 50(30), 643-645 (2001
5. Adverse events associated with 17D-derived yellow fever vaccination-United States, 2001-2002. MMWR. Morb. Mortal. Wkly Rep. 51(44), 989-993 (2002
6. Chan RC, Penney DJ, Little D, Carter IW, Roberts JA, Rawlinson WD. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet 358(9276), 121-122 (2001
7. Martin M, Tsai TF, Cropp B et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: A report of four cases. Lancet 358(9276), 98-104 (2001
8. Fox Jp, Penna PH. Behavior of 17D yellow fever virus in Rhesus monkeys: Relation to substrain, dose, and neural, or extraneural innoculaton. Am. J. Hyg. 38, 152-172. (1943
9. Stuart G. Reactions following vaccination against yellow fever. World Health Organization Yellow fever vaccine. WHO series, Geneva, Switzerland. (1956
10. Advisory Committee on Immunization Practices: Yellow fever vaccine: Recommendation of the U.S. Public Health Ann. Intern. Med. 71, 365-367 (1969
11. Barrett ADT, Gould EA. Comparison of neurovirulence of different strains of yellow fever virus in mice. J. Gen. Virol. 67(4), 631-637 (1986
12. European Medicines Agency. Guideline on good pharmacovigilance practices European Medicines Agency. Guideline on good pharmacovigilance practices (2012
13. Mcmahon AW, Eidex RB, Marfin AA et al. Neurologic disease associated with 17D-204 yellow fever vaccination: A report of 15 cases. Vaccine 25(10), 1727-1734 (2007
14. Gershman MD, Staples JE, Bentsi-Enchill AD et al. Viscerotropic disease: Case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 30(33), 5038-5 (2012
15. Rüggeberg JU, Gold MS, Bayas J-M et al. Anaphylaxis: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 25(31), 5675-5684 (2007
16. Pfister M, Ursteiner O, Hilfiker H et al. Immunogenicity and safety of Berna-YF compared with two other 17D Yellow Fever Vaccines in a phase II clinical trial. Am. J. Trop. Med. Hyg. 72(3), 339-346 (2005
17. Dumas R, Forrat R, Lang J, Farinelli T, Loutan L. Safety and immunogenicity of a new inactivated hepatitis A vaccine in concurrent administration with a typhoid fever vaccine or a typhoid fever + yellow fever vaccine. Adv. Ther. 14(4), 160-167 (1997
18. Ambrosch F, Fritzell B, Gregor J et al. Combined vaccination against yellow fever and typhoid fever: A comparative trial. Vaccine 12(7), 625-628 (1994
19. Nasidi A, Monath TP, Vandenberg J et al. Yellow fever vaccination and pregnancy: A four-year prospective study. Trans. R. Soc. Trop. Med. Hyg. 87(3), 337-339 (1993
20. Veit O, Niedrig M, Chapuis-Taillard C et al. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin. Infect. Dis. 48(5), 659-666 (2009
21. Poo J, Galan F, Forrat R et al. Live-Attenuated tetravalent dengue vaccine in Dengue-naive children, adolescents, and adults in mexico city: Randomized controlled Phase 1 trial of safety and immunogenicity. Ped. Infect. Dis. J. 30(1), (2011
22. Nasveld PE, Marjason J, Bennett S Concomitant or sequential administration of live attenuated japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: Randomized double-blind phase II evaluation of safety and immunogenicity Hum Vaccin. 6(11), 906-914 (2010
23. Carlos R, Amalia P, Mario MW. Evaluation of two yellow fever vaccines for routine immunization programs in Argentina Hum. Vaccin. 4(2), 121-126 (2008
24. Lang J, Zuckerman J, Clarke P, Barrett P, Kirkpatrick C, Blondeau C. Comparison of the immunogenicity and safety of two 17D yellow fever vaccines. Am. J. Trop. Med. Hyg. 60(6), 1045-1050 (1999
25. Werfel U, Popp W. Effects of yellow fever vaccination. Lancet 358(9296), 1909-1908 (2001
26. Marianneau P, Geprges-Courbot MC, Deubel V. Rarity of adverse effects after 17D yellow-fever vaccination. Lancet 358(9276), 84-85 (2001
27. Troillet N, Laurencet F. Effects of yellow fever vaccination. Lancet 358(9296), 1908-1909 (2001
28. Bae HG, Domingo C, Tenorio A et al. immune response during adverse events after 17d-derived yellow fever vaccination in Europe. J. Infect. Dis. 197(11), 1577-1584 (2008
29. Munoz J, Vilella A, Domingo C et al. Yellow fever-Associated viscerotropic disease in Barcelona, Spain. J. Travel Med. 15(3), 202-205 (2008
30. Hayes EB. Acute viscerotropic disease following vaccination against yellow fever. Trans. R. Soc. Trop. Med. Hyg. 101(10), 967-971 (2007
31. Doblas A, Domingo C, Bae HG et al. Yellow fever vaccine-Associated viscerotropic disease and death in Spain. J. Clin. Virol. 36(2), 156-158 (2006
32. Guimard T, Minjolle S, Polard E et al. Incidence of yellow fever vaccine-Associated neurotropic disease. Am. J. Trop. Med. Hyg. 81(6), 1141-1143 (2009
33. Kengsakul K, Sathirapongsasuti K, Punyagupta S. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J. Med. Assoc. Thai. 85(1), 131-134 (2002
34. Mounier G. Acute transverse myelitis following yellow fever vaccination. Abstract, Presented at: European Congress Pharmacology Soc (France) (2001
35. Andersen AMN, Wohlfahrt J, Christens P, Olsen J, Melbye M. Maternal age and fetal loss: Population based register linkage study. BMJ 320(7251), 1708-1712 (2000
36. Sanofi Pasteur SA. Corporate Core Data Sheet (CCDS) of Stamaril. Corporate Core Data Sheet (CCDS) of Stamaril (2008
37. Khromava AY, Eidex RB, Weld LH et al. Yellow fever vaccine: An updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 23(25), 3256-3263 (2005
38. Lindsey NP, Schroeder BA, Miller ER et al. Adverse event reports following yellow fever vaccination. Vaccine 26(48), 6077-6082 (2008
39. Eidex RB. History of thymoma and yellow fever vaccination. Lancet 364(9438), 936 (2004
40. Silva ML, Espirito-Santo LR, Martins MA et al. Clinical and immunological insights on severe, adverse neurotropic and viscerotropic disease following 17D yellow fever vaccination. Clin. Vaccine Immunol. 17(1), 118-126 (2010
41. Seligman SJ. Yellow Fever Virus Vaccine-Associated Deaths in Young Women. Emerging Infect. Dis. 17(10), 1891-1893 (2011
42. Monath TP. Review of the risks and benefits of yellow fever vaccination including some new analyses. Expert Rev. Vaccines 11(4), 427-448 (2012
43. Martins RDM, Maia MDLD, Santos EMD et al. Yellow fever vaccine post-marketing surveillance in Brazil. Procedia in Vaccinol. 2(2), 178-183 (2010
44. Kitchener S. Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX(R). Vaccine 22(17-18), 2103-2105 (2004
45. Breugelmans JG, Lewis RF, Agbenu E et al Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010. Vaccine 31(14), 1819-1829 (2013
46. Barban V, Girerd Y, Aguirre M et al. High stability of yellow fever 17D-204 vaccine: A 12-year restrospective analysis of large-scale production. Vaccine 25(15), 2941-2950 (2007
47. Gaucher D, Therrien R, Kettaf N et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J. Exp. Med. 205(13), 3119-3131 (2008
48. Domingo C, Niedrig M. Safety of 17D derived yellow fever vaccines. Expert Opin. Drug Safety 8(2), 211-221 (2009
49. Akondy RS, Monson ND, Miller JD et al. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J. Immunol. 183(12), 7919-7930 (2009
50. Da Costa Neves PC, De Souza Matos DC, Marcovistz R, Galler R. TLR expression and NK cell activation after human yellow fever vaccination. Vaccine 27(41), 5543-5549 (2009
51. Pulendran B. Learning immunology from the yellow fever vaccine: Innate immunity to systems vaccinology. Nat. Rev. Immunol. 9(10), 741-747 (2009
52. Pulendran B, Miller J, Querec TD et al. Case of yellow fever vaccine-Associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J. Infect. Dis. 198(4), 500-507 (2008
53. Cavalcanti DP, Salomao MA, Lopez-Camelo J, Pessoto MA. Early exposure to yellow fever vaccine during pregnancy. Trop. Med. Int. Health 12(7), 833-837 (2007
54. Thomas RE, Lorenzetti DL, Spragins W, Jackson D, Williamson T. Active and passive surveillance of yellow fever vaccine 17D or 17DD-Associated serious adverse events: Systematic review. Vaccine 29(28), 4544-4555 (2011
55. Suzano CES, Amaral E, Sato HK, Papaiordanou PM. The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil. Vaccine 24(9), 1421-1426 (2006
56. Tsai TF, Paul R, Lynberg MC, Letson GW. Congenital yellow fever virus infection after immunization in pregnancy. J Infect Dis. 168 (6), 1520-1523 (1993
57. Robert E, Vial T, Schaefer C, Arnon J, Reuvers M. Exposure to yellow fever vaccine in early pregnancy. Vaccine 17(3), 283-285 (1999
58. De La Rochebrochard E, Thonneau P. Paternal age and maternal age are risk factors for miscarriage; results of a multicentre European study. Hum. Rep. 17(6), 1649-1656 (2002
59. Monath TP, Gershman M, Staples E, Barrett A. Yellow fever vaccine. In: Vaccines, 6th edition. Plotkin SA, Orenstein W, Offit PA (Eds.), Elsevier, Philadelphia, PA, USA, 870-968 (2013
60. Ripoll C, Ponce A, Wilson M. Evaluation of two yellow fever vaccines for routine immunization programs in Argentina. Hum. Vaccin. 4, 121-126 (2008
61. Fitzner J, Coulibaly D, Ekra Kouadio D et al. Safety of the yellow fever vaccine during the September 2001 mass vaccination campaign in Abidjan, Ivory Coast. Vaccine 23(2), 156-162 (2004
62. Huhn GD, Brown J, Perea W et al. Vaccination coverage survey versus administrative data in the assessment of mass yellow fever immunization in internally displaced persons-Liberia, 2004. Vaccine 24(6), 730-737 (2006
63. Fernandes GC, Camacho LaB, Carvalho MS, Batista M, Almeida SMRD Neurological adverse events temporally associated to mass vaccination against yellow fever in Juiz de Fora, Brazil, 1999-2005. Vaccine 25(16), 3124-3128 (2007
64. Gubler DJ. The changing epidemiology of yellow fever and dengue, 1900 to 2003: Full circle? Comp. Immunol. Microbiol. Infect. Dis. 27(5), 319-330 (2004
65. Feroldi E, Capeding MR, Boaz M et al. Memory immune response and safety of a booster dose of Japanese encephalitis chimeric virus vaccine (JE-CV) in JE-CV-primed children. Hum. Vaccin. Immunother. 9(4), 10-19 (2013
66. Guy B, Barrere B, Malinowski C et al. From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 29(42), 7229-7241 (2011
67. Guy B, Guirakhoo F, Barban V et al. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 28(3), 632-649 (2010
68. Vital C, Vital A, Gbikpi-Benissan G et al. Postvaccinal inflammatory neuropathy: Peripheral nerve biopsy in 3 cases. J. Peripher. Nerv. Syst. 7(3), 163-167 (2002